Member Info for PL75

Selling Dx isn't putting up a for sale sign for the business, it's divesting what was a weird M&A strategy. As for the rest, all fair enough, luckily ava6k is near term and should be the bait for BP to realise it wouldn't cost them much more to buy the platform.

Bein, you're just jealous because you didn't copy and paste them. Get off your high horse.

Great advice.

O&W, if I wanted to read regurgitated content, I'd be on twatter reading Rah and TTBs post. No high horse, it's just pointless spam.

Great news!

5 lengthy posts first thing that say nothing. I thought we’d eliminated the twatter ramping bilge.

For those wondering where the updates are. New regime. CC isn’t Alan. I prefer it. She’s said what she’ll deliver. She’ll tell you when it’s done or if anything changes. Simple.

Just wondering when the ELMO convention is, anyone know?

So excited, I’ve doubled my holding.

Definitely worth looking here for rampers:

https://x.com/hashtag/AVCT?src=hashtag_click&f=live

Oh, that’s great news.

Timster, don't spoil the hype, the pumpers are in full flow and it's been a while, £1.37 before you know it. Enjoy the vinegar strokes...

Klaus has his hands tied, he’s not available right now. Reminds me, I must clean out his cage.

There’s an outbreak of posting this information:

Launch Diagnostics is a licensed reseller and distributor of Bosphore Monkeypox Detection Kit v1

Launch Diagnostics, part of the Avacta group, provides pathology solutions encompassing high quality diagnostic reagents and instrumentation from world leading manufacturer’s to the Health Services of the United Kingdom, Belgium, Luxemburg, France through Launch Diagnostics SAS and to the Republic of Ireland through ACCUSAY Diagnostics.

Offering a large portfolio of diagnostic kits, laboratory instrumentation and services, our product range has expanded over the years to include a comprehensive range of EIA, single test devices, serology products, molecular assays and instrumentation.

Phew. That's a relief. No one likes 'concerns'.

Also a bit odd considering everything I posted came from chatgpt and you claimed to have used it not long ago for your incorrect research. Ah well.

They’ve observed effective levels of dox. Few side effects. The holy grail. It works. Trolling can’t dispute the science. On track for H2 to see more data…

For conventional doxorubicin, achieving a concentration as high as 10,000 ng/g in the tumor microenvironment is generally not reported. The values in the 10,000 ng/g range are typically associated with specialized formulations or localized delivery methods, such as drug-eluting beads used in transcatheter arterial chemoembolization (TACE) for liver cancer, rather than with conventional systemic administration.

In conventional intravenous administration, the concentration of doxorubicin in tumor tissues usually falls within the 80 to 500 ng/g range, depending on various factors such as the tumor type, dose, and pharmacokinetic properties​ (AACR Journals)​ (AACR Journals).

If you need a reference specifically showing a concentration of 10,000 ng/g or more for conventional doxorubicin, it would not align with standard pharmacokinetic data for this method of delivery. The high concentration values are primarily associated with localized and controlled release systems, not with standard IV dosing.

Cba to look back at presentations, but Alan suggested the concentrations from AVA6k were greater than typical. Another sulphuric stench has appeared…

Here are references that provide more insight into the concentration of doxorubicin in the tumor microenvironment (TME) shortly after administration:

A study on brain tumors in rats found that following intravenous administration of free doxorubicin, peak tumor concentrations of 80 to 240 ng/g were observed 1 to 4 hours post-injection. This study highlights the variability based on tumor type and suggests that different tumors may exhibit different pharmacokinetics​ (AACR Journals).

Another study focusing on various types of tumors reported similar ranges of doxorubicin concentrations shortly after administration, typically between 100 to 500 ng/g depending on the specific tumor environment and the presence of the Enhanced Permeability and Retention (EPR) effect, which aids in the drug’s accumulation within the tumor​ (SpringerLink).

A systematic review on the pharmacokinetics of doxorubicin noted the variability in drug concentration within tumors, with ranges influenced by administration methods and the type of tumor. The concentrations can vary, but often fall within the 80 to 240 ng/g range in conventional settings​ (MDPI).

These references collectively underscore the importance of tumor type, administration method, and specific experimental conditions in determining the concentration of doxorubicin in the TME.

This. Is. Incredible. I’ve just doubled my holding.

Not difficult, she’s now the CEO, her last job was in the lab.

Wetherby Whaler. Being kept afloat by Alan, enjoying his time off with a daily fish supper

I'd say no, their Head of Colleague Chuminess talking about having an away day hasn't prepared me for a new partnership/alliance in the slightest. Nice to see the Project Optimus easter egg though - clearly deliberately included.

Incidentally, they love job title inflation, when you look at the accounts it's good to see that all these Chiefs aren't picking up six figures a pop, otherwise given the small number of employees they'd definitely have too many chiefs and not enough indians. You probably can't use that phrase anymore, apologies to any native americans reading that phrase.